Active	Status	Sponsor type	Region	Phase	Filter
15 Active 0 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Fugazzola, Laura
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer	Active, not recruiting	3	291	Europe, Canada, Japan, US, RoW	Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib	Loxo Oncology, Inc., Eli Lilly and Company	Medullary Thyroid Cancer	05/23	02/26
THRIVE, NCT05176639 / 2021-006794-37: A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants with Thyroid Eye Disease (TED) ( )	Active, not recruiting	3	154	Europe, Canada, US, RoW	Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED), VRDN-001 Phase 3 Cohort (THRIVE), VRDN-001 Placebo	Viridian Therapeutics, Inc., Viridian Therapeutics, Inc.	Thyroid Eye Disease	07/24	03/25
Persani, Luca LP
No trials found